Plant-based vaccines against viruses

Rybicki, Edward P.

doi:10.1186/preaccept-2088894788140228

Cited by 58 publications

(87 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tobacco cell derived vaccine against the Newcastle disease virus was the first licensed plant-derived vaccine [241]. ZMapp used to fight for Ebolavirus infection was a plant-made antibody as a hot spot recently reported by scientific news [242]. …”

Section: Other Vaccines For Plaguementioning

confidence: 99%

Plague Vaccines: Status and Future

Sun

2016

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Three major plague pandemics caused by the gram-negative bacterium Yersinia pestis have killed nearly 200 million people in human history. Due to its extreme virulence and the ease of its transmission, Y. pestis has been used purposefully for biowarfare in the past. Currently, plague epidemics are still breaking out sporadically in most of parts of the world, including the United States. Approximately 2000 cases of plague are reported each year to the World Health Organization. However, the potential use of the bacteria in modern times as an agent of bioterrorism and the emergence of a Y. pestis strain resistant to eight antibiotics bring out severe public health concerns. Therefore, prophylactic vaccination against this disease holds the brightest prospect for its long-term prevention. Here, we summarize the progress of the current vaccine development for counteracting plague.

show abstract

Section: Other Vaccines For Plaguementioning

confidence: 99%

Plague Vaccines: Status and Future

Sun

2016

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

show abstract

“…The focus of PMF technology is to produce enzymes, growth factors, antibodies, vaccines and medicines for the treatment of major health challenges, chronic and infectious diseases (Stoger et al, 2014). Plant-made therapeutic products have recently been reported in experimental endeavors against major diseases, such as malaria (Gregory & Mayfield, 2014), Alzheimers (Rosales-Mendoza et al, 2014) and many other human and animal viruses (Rybicki, 2014). In 2012, a high-profile drug called ElelysoÔ (taliglucerase alfa) was approved in the USA as the first plant-made biodrug for the treatment of the type 1 Gaucher's disease, a rare genetic disorder.…”

Section: Applications Of Pmfsmentioning

confidence: 99%

Molecular farming on rescue of pharma industry for next generations

Moustafa

Makhzoum

Trémouillaux-Guiller

2015

Critical Reviews in Biotechnology

View full text Add to dashboard Cite

Recombinant proteins expressed in plants have been emerged as a novel branch of the biopharmaceutical industry, offering practical and safety advantages over traditional approaches. Cultivable in various platforms (i.e. open field, greenhouses or bioreactors), plants hold great potential to produce different types of therapeutic proteins with reduced risks of contamination with human and animal pathogens. To maximize the yield and quality of plant-made pharmaceuticals, crucial factors should be taken into account, including host plants, expression cassettes, subcellular localization, post-translational modifications, and protein extraction and purification methods. DNA technology and genetic transformation methods have also contributed to great parts with substantial improvements. To play their proper function and stability, proteins require multiple post-translational modifications such as glycosylation. Intensive glycoengineering research has been performed to reduce the immunogenicity of recombinant proteins produced in plants. Important strategies have also been developed to minimize the proteolysis effects and enhance protein accumulation. With growing human population and new epidemic threats, the need for new medications will be paramount so that the traditional pharmaceutical industry will not be alone to answer medication demands for upcoming generations. Here, we review several aspects of plant molecular pharming and outline some important challenges that hamper these ambitious biotechnological developments.

show abstract

“…The Caliber facility, which went from groundbreaking to final product (an H1N1 influenza subunit vaccine) in < 2 years, can now process 3,500 kg of biomass per week with its automated system (54). Additionally, the FDA recently approved taliglucerase alfa (ELELYSO ® ), an injectable drug made in carrot cells, to treat Gaucher disease (46, 108). However, except Fraunhofer, these platforms still require purification of expressed proteins.…”

Section: Clinical Development Of Chloroplast-made Biopharmaceuticalsmentioning

confidence: 99%

Vaccination via Chloroplast Genetics: Affordable Protein Drugs for the Prevention and Treatment of Inherited or Infectious Human Diseases

2016

View full text Add to dashboard Cite

Plastid-made biopharmaceuticals treat major metabolic or genetic disorders, including Alzheimer’s, diabetes, hypertension, hemophilia, and retinopathy. Booster vaccines made in chloroplasts prevent global infectious diseases, such as tuberculosis, malaria, cholera, and polio, and biological threats, such as anthrax and plague. Recent advances in this field include commercial-scale production of human therapeutic proteins in FDA-approved cGMP facilities, development of tags to deliver protein drugs to targeted human cells or tissues, methods to deliver precise doses, and long-term stability of protein drugs at ambient temperature, maintaining their efficacy. Codon optimization utilizing valuable information from sequenced chloroplast genomes enhanced expression of eukaryotic human or viral genes in chloroplasts and offered unique insights into translation in chloroplasts. Support from major biopharmaceutical companies, development of hydroponic production systems, and evaluation by regulatory agencies, including the CDC, FDA, and USDA, augur well for advancing this novel concept to the clinic and revolutionizing affordable healthcare.

show abstract

Plant-based vaccines against viruses

Cited by 58 publications

References 82 publications

Plague Vaccines: Status and Future

Plague Vaccines: Status and Future

Molecular farming on rescue of pharma industry for next generations

Vaccination via Chloroplast Genetics: Affordable Protein Drugs for the Prevention and Treatment of Inherited or Infectious Human Diseases

Contact Info

Product

Resources

About